P3 Health Partners Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted EBITDA: $26 million, significantly improved from a loss of $22 million in Q1 2025.

Revenue: $386 million, up from $373 million year-over-year, despite a decline in membership.

At-risk Membership: Approximately 106,000, down from 118,000 in Q1 2025 due to strategic exits from underperforming contracts.

Medical Margin: $74 million with a medical loss ratio of 85.2% (adjusted).

Cash Position: Ended the quarter with $25 million in cash and equivalents.

Revised Full-Year 2026 Adjusted EBITDA Outlook: Increased to a range of $20 million to $60 million, with a midpoint of $40 million.

2Strategic Updates and Business Highlights

Operational Improvements: Focus on contract restructuring, operational redesign, and alignment between clinical and financial infrastructure has led to improved performance.

Payer Contract Enhancements: Improved risk funding and cost accountability structures have resulted in a 15% year-over-year increase in Medicare Advantage funding rates.

Clinical Execution: Enhanced medical cost management and quality execution are yielding positive results, with a flat medical expense trend compared to a 7% trend seen in peers.

Partnership Expansion: New partnership in Nebraska added 28,600 lives under management, demonstrating a disciplined growth strategy.

3Forward Guidance and Outlook

The company is optimistic about the Medicare Advantage environment, anticipating continued margin expansion opportunities.

The focus will remain on improving operational execution and expanding payer relationships with a pathway to deeper delegation.

The revised outlook reflects confidence in the underlying operating trajectory and structural improvements made.

4Bad News, Challenges, or Points of Concern

Membership Decline: The drop in at-risk membership indicates a strategic shift that may pose risks to revenue stability in the short term.

Dependence on Payer Relationships: Future success hinges on maintaining and expanding partnerships, particularly in achieving deeper delegation with payers.

Market Competition: The industry is experiencing increasing competitive pressures, with peers guiding to higher medical cost trends, which P3 aims to counteract through operational efficiency.

5Notable Q&A Insights

Utilization Management: Discussion around the impact of Part A and B costs showed proactive management in reducing costs, particularly in Part B.

Payer Partner Expansion: The improved financial position and balance sheet are expected to enhance P3's attractiveness as a partner, facilitating future growth.

Delegation Pathway: The delegation process is gradual and requires meeting specific contractual milestones, indicating a cautious but structured approach to expanding operational control. Overall, P3 Health Partners demonstrated strong financial performance in Q1 2026, driven by strategic operational improvements and a focus on clinical execution, while navigating challenges related to membership and competitive pressures. The outlook remains positive, with a clear focus on enhancing payer relationships and operational efficiency.